Brouwers J R, Van der Kam H J, Sijtsma J, Proost J H
Department of Clinical Pharmacy and Pharmacokinetics, General Hospital De Tjongerschans, Heerenveen, The Netherlands.
Pharm Weekbl Sci. 1990 Oct 19;12(5):182-3. doi: 10.1007/BF01980042.
The effect of ferrous fumarate on the relative bioavailability of ciprofloxacin after a single 500 mg oral dose of ciprofloxacin was studied in eight healthy males. Blood samples were collected at regular intervals 0-24 h post-dose. Urine was collected during 24 h to determine the cumulative urine excretion of ciprofloxacin. Ciprofloxacin concentrations in serum and urine were determined by high pressure liquid chromatography. Mean area under the serum concentration-time curve decreased significantly (P less than 0.001) after ciprofloxacin was taken with 200 mg ferrous fumarate. The relative bioavailability was 30% when ciprofloxacin was given with ferrous fumarate. The maximum blood level decreased from 2.1 +/- 0.9 (control) to 0.6 +/- 0.2 mg/l (with ferrous fumarate). Further studies are needed to determine if chronic treatment with ferrous fumarate further decreases the relative bioavailability. For the moment administration of ciprofloxacin with ferrous fumarate should therefore be avoided.
在8名健康男性中研究了单次口服500毫克环丙沙星后,富马酸亚铁对环丙沙星相对生物利用度的影响。给药后0至24小时定期采集血样。收集24小时内的尿液以测定环丙沙星的累积尿排泄量。血清和尿液中环丙沙星浓度通过高压液相色谱法测定。与200毫克富马酸亚铁一起服用环丙沙星后,血清浓度-时间曲线下的平均面积显著降低(P小于0.001)。环丙沙星与富马酸亚铁一起服用时,相对生物利用度为30%。最大血药浓度从2.1±0.9(对照)降至0.6±0.2毫克/升(与富马酸亚铁一起服用时)。需要进一步研究以确定富马酸亚铁的长期治疗是否会进一步降低相对生物利用度。因此,目前应避免环丙沙星与富马酸亚铁同时给药。